Matts Kågedal
Matts Kågedal
Verified email at
Cited by
Cited by
Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity
M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ...
Pharmaceutical research 14, 176-180, 1997
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region
M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ...
Neuroimage 82, 160-169, 2013
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model
PH Zingmark, M Kågedal, MO Karlsson
Journal of pharmacokinetics and pharmacodynamics 32, 261-281, 2005
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33, 75-91, 2006
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde
International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013
Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens
D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ...
CPT: Pharmacometrics & Systems Pharmacology 6 (6), 401-408, 2017
Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study
WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ...
The Journal of Clinical Pharmacology 59 (5), 702-716, 2019
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ...
Neuroimage 61 (4), 849-856, 2012
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C …
K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ...
Psychopharmacology 213, 533-545, 2011
Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study
A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ...
Drugs in R & D 6, 139-147, 2005
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug …
MZ Liao, D Lu, M Kågedal, D Miles, D Samineni, SN Liu, C Li
Clinical Pharmacology & Therapeutics 110 (5), 1216-1230, 2021
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
S Kawakatsu, R Bruno, M Kågedal, C Li, S Girish, A Joshi, B Wu
British Journal of Clinical Pharmacology 87 (6), 2493-2501, 2021
True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers
M Kågedal, PH Zingmark, C Hedlund, R Yates
American Journal of Drug Delivery 3, 133-140, 2005
PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ...
European Neuropsychopharmacology 18, S270-S270, 2008
Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers
J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz
European Journal of Pain 17 (10), 1465-1471, 2013
A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime.
M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ...
Journal of clinical pharmacology 47 (8), 1043-1049, 2007
Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy
E Reyner, B Lum, J Jing, M Kagedal, JA Ware, LJ Dickmann
Clinical and Translational Science 13 (2), 410-418, 2020
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li
Cancer Chemotherapy and Pharmacology 80, 1147-1159, 2017
Early phase drug development for treatment of chronic pain—Options for clinical trial and program design
J Kalliomäki, F Miller, M Kågedal, R Karlsten
Contemporary clinical trials 33 (4), 689-699, 2012
Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration
CC Wykoff, PA Campochiaro, DJ Pieramici, AM Khanani, S Gune, M Maia, ...
Ophthalmology and Therapy 11 (5), 1705-1717, 2022
The system can't perform the operation now. Try again later.
Articles 1–20